Skip to content

Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00749619
Enrollment
Unknown
Registered
2008-09-09
Start date
2007-05-31
Completion date
2008-08-31
Last updated
2008-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease, Hemodialysis

Keywords

Tunneled Cuffed Catheter, Catheter Lock Solution, Catheter Related Bacteremia

Brief summary

Addition of Heparin to the Catheter Lock Solution (CLS): Taurolock-TM will improve the vascular patency compared to Taurolock-TM alone , in hemodialysis patients with Tunneled Cuffed Catheter(TCC) as vascular access.

Detailed description

Bacteremia and thrombosis are the major complications of TCC used for hemodialysis.Instilation of CLS containing antibiotic-anticoagulant solution in the end of each dialysis session till the next dialysis ,can prevent Catheter related bacteremia (CRB).In previous study in our department, Taurolock-TM decreased the rate of CRB but increased the incidence of catheter malfunction. The aim of the study is to investigate the influence of of Heparin addition to CLS-Taurolock- TM ( Taurolidine &citrate 4%) in prevention of catheter patency problems in HD patients with TCC, in addition to CRB prevention. Methods : Patients with newly inserted TCC for HD enrolled and randomized to receive one of three CLS types : group 1- Taurolock-TM, Group 2 - Taurolock-TM and Heparin , Group 3- Heparin .Patients were followed for 6 monthes. The objective of the study is to investigate the effect of Taurolock TM with heparin on the rate of CRB and vascular patency.

Interventions

OTHERCatheter Lock Solution Taurolidine and Citrate
OTHERCatheter Lock Solution :Taurolidine and Citrate and Heparin
OTHERCatheter Lock Solution : Heparin

Sponsors

Western Galilee Hospital-Nahariya
Lead SponsorOTHER_GOV

Study design

Primary purpose
PREVENTION

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Hemodialysis patients with new TCC * Informed Consent

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026